These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 10621514)
21. Medical research on humans: regulation in Switzerland, the European Union, and the United States. Schott M Food Drug Law J; 2005; 60(1):45-77. PubMed ID: 15940854 [No Abstract] [Full Text] [Related]
22. [Clinical trials in cancerology]. Rider WD Vie Med Can Fr; 1973 Oct; 2(10):946-9. PubMed ID: 4761491 [No Abstract] [Full Text] [Related]
23. [Problems in conducting clinical trials for cancer patients]. Kondo M Gan To Kagaku Ryoho; 1996 Jan; 23(2):151-5. PubMed ID: 8611042 [TBL] [Abstract][Full Text] [Related]
24. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Roukos DH; Tzakos A; Zografos G Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000 [No Abstract] [Full Text] [Related]
25. Dilemmas in paying for clinical research: the view from the IRB. Lind SE IRB; 1987; 9(2):1-5. PubMed ID: 11649900 [No Abstract] [Full Text] [Related]
26. The investigational new drug application--who benefits? Freireich EJ Nat Clin Pract Oncol; 2006 Feb; 3(2):62-3. PubMed ID: 16462826 [No Abstract] [Full Text] [Related]
27. [Clinical trials and studies of the German Society for Paediatric Oncology and Haematology (GPOH) and the European Directive for the Implementation of Good Clinical Practice in the Conduct of Clinical Trials]. Graf N; Göbel U Klin Padiatr; 2004; 216(3):129-31. PubMed ID: 15175956 [No Abstract] [Full Text] [Related]
28. The conduct of therapeutic trials in cancer medicine. Rudnick S; Capizzi RL Semin Oncol; 1977 Jun; 4(2):255-8. PubMed ID: 327556 [No Abstract] [Full Text] [Related]
29. [Ethical perspective in clinical trials for drug development]. Fujiwara Y Nihon Rinsho; 2015 Feb; 73 Suppl 2():693-700. PubMed ID: 25831850 [No Abstract] [Full Text] [Related]
30. When informed consent is not required in studies. Maloney DM Hum Res Rep; 2006 Jun; 21(6):3. PubMed ID: 17111532 [No Abstract] [Full Text] [Related]
31. U.S. medical research in the developing world: ignoring Nuremberg. Roman J Cornell J Law Public Policy; 2002; 11(2):441-60. PubMed ID: 12058774 [No Abstract] [Full Text] [Related]
32. Cancer drugs. Weighing the risks and benefits. Bren L FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832 [TBL] [Abstract][Full Text] [Related]
33. The basics of human subjects protection. Yoder LH Medsurg Nurs; 2006 Apr; 15(2):95-8; quiz 99. PubMed ID: 16700248 [No Abstract] [Full Text] [Related]
34. Can we ensure that all research subjects give valid consent? Wendler D Arch Intern Med; 2004 Nov; 164(20):2201-4. PubMed ID: 15534155 [TBL] [Abstract][Full Text] [Related]
35. Rate of refusal to participate in clinical trials. Shimm DS; Spece RG IRB; 1992; 14(2):7-9. PubMed ID: 11651246 [No Abstract] [Full Text] [Related]
36. [Ethics committees in USA--background and development. Responsible conductors of clinical trials required for risk minimization]. Lund LH Lakartidningen; 2008 Jan 9-15; 105(1-2):42-4. PubMed ID: 18293746 [No Abstract] [Full Text] [Related]
38. Living for a cure. Rieger PT Oncol Nurs Forum; 1999; 26(10):1581. PubMed ID: 10573672 [No Abstract] [Full Text] [Related]
39. Informed consent in clinical research: policies and practices in Singapore. Ramachandran AJ J Biolaw Bus; 2003; 6(1):65-75. PubMed ID: 15239181 [TBL] [Abstract][Full Text] [Related]
40. Phase I trials in cancer treatment. The maximum tolerated dose: a barbarian guideline. Degos L Hematol J; 2000; 1(4):219. PubMed ID: 11920193 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]